SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksASH.L Regulatory News (ASH)

  • There is currently no data for ASH

Directorate Change

23 Nov 2009 17:06

RNS Number : 9522C
Ashley House PLC
23 November 2009
 



Ashley House plc (or "the Company")

Director Change

Ashley House plc the Primary Care Infrastructure specialist, announces today that following the recent acquisition of Sapphire Primary Care Developments ("SPCD") and Lloydspharmacy's resulting 10% shareholding in the Company, Andrew Willetts (46), Finance Director of Lloydspharmacy will join the Board of Ashley House plc as a non-executive director effective immediately 

Andrew Willetts graduated from Keble CollegeOxford in 1985 with a degree in Modern History before going on to qualify as a chartered accountant with what is now PricewaterhouseCoopers in 1991. Since then he has held senior financial roles in a number of companies in the retail and wholesale sectors, including Waterstones Booksellers, and most recently as Director of Shared Services at Hagemeyer (now Rexel SA), prior to joining Lloydspharmacy in July 2003 as Head of Management Reporting.

Andrew was appointed to the position of Director of Financial Operations for Lloydsparmacy, effective 1st January 2005 before being appointed Finance Director Designate on 1st December 2006. Following a three month secondment to Celesio in Stuttgart he became Finance Director of Lloydspharmacy on 1st April 2007. He is also a trustee of the Group pension fund and had main board responsibility for Sapphire Primary Care Developments. 

Andrew's current directorships include the following trading companies

AAH LIMITED

AAH Lloyds Insurance (IoM) Limited

ADMENTA HOLDINGS LIMITED

ADMENTA UK PLC

JOHN BELL & CROYDEN LIMITED

LLOYDS CHEMISTS LIMITED

LLOYDS GROUP PROPERTIES LIMITED

LLOYDS PHARMACY LIMITED

LLOYDS PROPERTIES LIMITED

LLOYDS RETAIL CHEMISTS LIMITED

MPWB (ROMFORD) LIMITED

PHARMAGEN LIMITED

SAVORY & MOORE LIMITED

STEPHEN SMITH LIMITED

Including the companies set out above, Andrew is a director of 387 subsidiary companies of Admenta UK plc, the holding company of Lloydspharmacy. The majority of these companies are dormant. However, a full list of the companies of which Andrew is a director is available from Ashley House on request.

Tony Walters formerly Managing Director of SPCD will be an alternate director to Andrew Willetts. 

Tony (42) graduated with a BA (Hons) Degree in Accounting from Portsmouth Polytechnic (University of Portsmouth) in 1989 before qualifying as a Chartered Accountant in 1992 with Burnett Swayne, Tony has an Executive MBA from Warwick University which he completed in 2003.

Tony joined the Celesio Group in 1996 as Acquisitions Controller for Hills Pharmacy and was involved in the Due Diligence and integration of Lloyds Chemist Plc in 1997 before becoming Director of Acquisitions & Development for Lloydspharmacy in 1999. In 2000 Tony was part of the leadership team that set up what was to become Sapphire Primary Care Developments joining the board of SPCwhen it became a separate company. In 2004 Tony merged Lloydspharmacy's Acquisitions & Development, Property, Shopfitting and Store planning Departments into one new Property & Development department with over 70 personnel, becoming Director of Property & Development before joining Celesio AG in 2005 based in Stuttgart as Director of European Pharmacy Expansion, with the responsibility of looking at market entry into 10 potential new European Countries. In 2006 Tony returned to the UK to become Managing Director of Sapphire Primary Care Developments Limited.

Tony has represented Sapphire as a Director on two Infracare and 2 GB Consortium Companies and currently has responsibility for Lloydspharmacy Acquisitions and Strategy.

The names of all companies and partnerships of which Tony has been a director or partner at any time in the previous five years are set out below:

Sapphire Primary Care Developments Ltd

SPCD (Balsall Common) Ltd

SPCD (Crawcrook) Ltd

SPCD (Silsden) Ltd

SPCD (Didcot) Ltd

SPCD (Davyhulme) Ltd

SPCD (Kincaidston) Ltd

SPCD (Midsomer Norton) Ltd

SPCD (Paisley) Ltd

SPCD (Rugeley) Ltd

SPCD (Sutton in Ashfield) Ltd

SPCD (Northwich) Ltd

SPCD (Shavington) Ltd

Infracare (Midlands) Ltd

Infracare (South West) Ltd

Infracare Dudley Ltd

Infracare Oxford Ltd

Infracare Bristol Ltd

Infracare (South) Ltd

GB Consortium 1 Ltd

GB Consortium 2 Ltd

CCP Fundco 1 Ltd

Coventry Care Partnership Ltd

Jonathan Holmes, Chief Executive of Ashley House plc, said:

 "We are delighted to welcome Andrew to our Board as we look to strengthen our team and develop a close working relationship with our new joint venture partnersAndrew and Tony both bring a wealth of experience particularly in the pharmacy area and we look forward to the future successes of both Ashley House and Lloydspharmacy"

There are no other matters which are required to be announced pursuant to paragraph (g) of Schedule 2 to the AIM Rules.

Enquiries

Ashley House plc 

Jonathan Holmes, Chief Executive

Bruce Walker, Finance Director

Tel: 01628 600340

Citigate Dewe Rogerson 

Sarah Gestetner / Ged Brumby

Tel: 020 7638 9571

Numis Securities Limited 

Nominated Adviser: Oliver Cardigan / Simon Blank

Corporate Broker: David Poutney

Tel: 020 7260 1000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAILFIDLFLVFIA
Date   Source Headline
29th Jun 20189:08 amRNSDirectorate change
10th May 20187:00 amRNSHolding(s) in Company
9th May 20182:05 pmRNSSecond Price Monitoring Extn
9th May 20182:00 pmRNSPrice Monitoring Extension
9th May 20187:00 amRNSTrading Update
3rd May 20185:38 pmRNSDirector/PDMR Shareholding
6th Mar 20183:00 pmRNSDirector Dealing
5th Mar 20187:00 amRNSFinancial Close Scarborough Extra Care
1st Mar 20187:00 amRNSAppointment of Finance Director
23rd Feb 201811:54 amRNSHolding(s) in Company
14th Feb 20188:51 amRNSSale of Pharmacy Interest to Repay Debt - Amended
14th Feb 20187:00 amRNSSale of Pharmacy Interest to Repay Debt
2nd Feb 20189:32 amRNSHolding(s) in Company
31st Jan 20187:00 amRNSInterim Results
30th Jan 20184:31 pmRNSDirectors' & PDMRs' Dealings
22nd Dec 20171:07 pmRNSDirector/PDMR Shareholding
15th Dec 20171:56 pmRNSJoint Venture with Morgan Sindall Investments Ltd
24th Nov 20177:00 amRNSUpdate
7th Nov 201711:00 amRNSHolding(s) in Company
31st Oct 20172:28 pmRNSDirectors' & PDMRs' Dealings
26th Oct 20177:00 amRNSUpdate
25th Oct 201712:35 pmRNSResult of AGM
3rd Oct 201710:45 amRNSHolding(s) in Company
3rd Oct 20179:25 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSPreliminary Results For The Year End 30 April 2017
28th Jul 20174:45 pmRNSDirectors' & PDMRs' Dealings
4th Jul 20174:27 pmRNSDebt Facility from Related Party
28th Apr 20172:20 pmRNSDirectors' & PDMRs' dealings
25th Apr 20173:16 pmRNSDebt Facility from Related Party
27th Mar 201711:09 amRNSDirector Dealing
17th Mar 20173:42 pmRNSDirector Dealing
14th Mar 20171:11 pmRNSAcquisition and Trading Update
22nd Feb 201712:03 pmRNSPosting of Interim Report
30th Jan 20171:27 pmRNSDirectors' & PDMRs' dealings
26th Jan 20177:00 amRNSInterim Report 2016
17th Jan 201710:27 amRNSHolding(s) in Company
7th Dec 20167:00 amRNSReplacement Debt Facility from Related Party
28th Oct 20168:41 amRNSDirectors' & PDMRs' dealings
15th Sep 201610:48 amRNSResult of AGM
23rd Aug 20167:00 amRNSReport and Accounts / AGM
28th Jul 20167:00 amRNSDirectors' & PDMRs' Dealings
13th Jul 201611:58 amRNSDirector/PDMR Shareholding
13th Jul 20167:00 amRNSPreliminary results
29th Apr 20167:00 amRNSTotal Voting Rights
28th Apr 201610:22 amRNSDirectors' & PDMRs' dealings
29th Mar 20167:00 amRNSDirectors & PDMRs dealings
1st Mar 201611:09 amRNSDirector Dealing
10th Feb 20167:00 amRNSAdmission Application Announcement
5th Feb 20165:27 pmRNSPosting of Interim Report
26th Jan 20167:00 amRNSInterim Report 2015

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.